Abstract

Background: Diabetic retinopathy (DR) is one of the most important microvascular diseases of diabetes. Our previous research demonstrated that bile acid G-protein-coupled membrane receptor (TGR5), a novel cell membrane receptor of bile acid, ameliorates the vascular endothelial cell dysfunction in DR. However, the precise mechanism leading to this alteration remains unknown. Thus, the mechanism of TGR5 in the progress of DR should be urgently explored. Methods: In this study, we established high glucose (HG)-induced human retinal vascular endothelial cells (RMECs) and streptozotocin-induced DR rat in vitro and in vivo. The expression of TGR5 was interfered through the specific agonist or siRNA to study the effect of TGR5 on the function of endothelial cell in vitro. Western blot, immunofluorescence and fluorescent probes were used to explore how TGR5 regulated mitochondrial homeostasis and related molecular mechanism. The adeno-associated virus serotype 8-shTGR5 (AAV8-shTGR5) was performed to evaluate retinal dysfunction in vivo and further confirm the role of TGR5 in DR by HE staining, TUNEL staining, PAS staining and Evans Blue dye. Results: We found that TGR5 activation alleviated HG-induced endothelial cell apoptosis by improving mitochondrial homeostasis. Additionally, TGR5 signaling reduced mitochondrial fission by suppressing the Ca2+-PKCδ/Drp1 signaling and enhanced mitophagy through the upregulation of the PINK1/Parkin signaling pathway. Furthermore, our result indicated that Drp1 inhibited mitophagy by facilitating the hexokinase (HK) 2 separation from the mitochondria and HK2-PINK1/Parkin signaling. In vivo, intraretinal microvascular abnormalities, including retinal vascular leakage, acellular capillaries and apoptosis, were poor in AAV8-shTGR5-treated group under DR, but this effect was reversed by pretreatment with the mitochondrial fission inhibitor Mdivi-1 or autophagy agonist Rapamycin. Conclusion: Overall, our findings indicated that TGR5 inhibited mitochondrial fission and enhanced mitophagy in RMECs by regulating the PKCδ/Drp1-HK2 signaling pathway. These results revealed the molecular mechanisms underlying the protective effects of TGR5 and suggested that activation of TGR5 might be a potential therapeutic strategy for DR.

Highlights

  • Diabetic retinopathy (DR) is one of the most frequent microvascular complications of diabetes mellitus (DM) and the leading cause of blindness in the working-age population (Daskivich et al, 2017)

  • Our results show that Bile Acid G-Protein-Coupled Membrane Receptor (TGR5) inhibits mitochondrial fission and/or enhances mitophagy by regulating dynamin-related protein 1 (Drp1)-Hexokinase II (HK2) signaling, thereby lowering endothelial dysfunction and alleviating DR progression

  • The results revealed that the cell survival rate was significantly elevated in the INT-777treated group compared with the high glucose (HG)-treated cells. dosedependent increase of cell survival rates occurred with doses in the range 1–30 μM in HG + INT-777-treated groups

Read more

Summary

Introduction

Diabetic retinopathy (DR) is one of the most frequent microvascular complications of diabetes mellitus (DM) and the leading cause of blindness in the working-age population (Daskivich et al, 2017). By the year 2040, the number of diabetics worldwide is expected to rise to 642 million, and about one-third of patients may suffer a diabetic retinal disease (Weber et al, 2016). Hyperglycaemia causes endothelial apoptosis and pericyte loss, thereby promoting the formation of acellular capillaries and leading to blood–retina barrier (BRB) breakdown (Roy and Kim, 2021). We can speculate that the improvement in the retinal endothelial function may retard the progression of DR. Our previous research demonstrated that bile acid G-proteincoupled membrane receptor (TGR5), a novel cell membrane receptor of bile acid, ameliorates the vascular endothelial cell dysfunction in DR. The mechanism of TGR5 in the progress of DR should be urgently explored

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call